department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Novartis Gene Therapies · pharmadog

PUBLIC COMPANY

Novartis Gene Therapies

updated 1mo ago

community read0 votes

pipeline

1

marketed

1

phase 3

0

catalysts ytd

0

approvals ytd

0

recalls ytd

0

Pipeline(1)

pipeline depth1 products

1Marketed

onasemnogene abeparvovec

Spinal Muscular Atrophy (SMA)

Upcoming

no upcoming catalysts on record

Recent(90d)

nothing in the last 90 days

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view Novartis Gene Therapies jobs →

News

no news has mentioned this company yet

identifiers

source

globaldata

mentioned in

0news items

entity-linker matched

Active trials

phase3Single-Dose Gene Replacement Therapy Using for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copiescompletedn=2
phase3Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2completedn=30
phase3Single-Dose Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1completedn=33
phase3Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1completedn=22
phase1Study of Intrathecal Administration of Onasemnogene Abeparvovec-xioi for Spinal Muscular Atrophyterminatedn=32
phase3Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioiactive not recruitingn=85
—Long-Term Follow-up Study for Patients From AVXS-101-CL-101active not recruitingn=13

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?